aTyr Pharma: Funding, Investors & Team (Sep 2026)
aTyr Pharma is a biotech company that specializes in discovering and creating protein biologics for human therapeutics. The company holds a strong intellectual property portfolio in Physiocrine-based compositions and potential therapeutic uses. The main focus of aTyr's programs is on immunomodulation disorders related to inflammation and immunity, which are currently in the preclinical development stage. The company's primary product candidate is ATYR1923, which targets the neuropilin-2 receptor to reduce immune activation in interstitial lung diseases. Founded by Professor Paul Schimmel from The Scripps Research Institute, aTyr is supported by prominent life sciences investors including Alta Partners, Cardinal Partners, Domain Associates, and Polaris Ventures.
aTyr Pharma has raised $30.7M across 1 funding round on record, the most recent an undisclosed round of $30.7M announced in Aug 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
aTyr Pharma Company Profile and Key Stats
Latest funding round on record: Aug 2025.
aTyr Pharma Funding Rounds
aTyr Pharma Founders and Leadership Team
No contact details are on record for this team yet.
aTyr Pharma Funding Compared to Other Biotechnology Startups
aTyr Pharma's latest round of $30.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like aTyr Pharma in Biotechnology and San Diego
Companies Similar to aTyr Pharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
aTyr Pharma Funding FAQs
What does aTyr Pharma do?
aTyr Pharma is a biotech company that specializes in discovering and creating protein biologics for human therapeutics. The company holds a strong intellectual property portfolio in Physiocrine-based compositions and potential therapeutic uses. The main focus of aTyr's programs is on immunomodulation disorders related to inflammation and immunity, which are currently in the preclinical development stage. The company's primary product candidate is ATYR1923, which targets the neuropilin-2 receptor to reduce immune activation in interstitial lung diseases. Founded by Professor Paul Schimmel from The Scripps Research Institute, aTyr is supported by prominent life sciences investors including Alta Partners, Cardinal Partners, Domain Associates, and Polaris Ventures.
How much funding has aTyr Pharma raised?
aTyr Pharma has raised $30.7M across 1 round on record. The most recent is an undisclosed round of $30.7M announced in Aug 2025.
When did aTyr Pharma last raise funding?
aTyr Pharma's most recent funding round on record is an undisclosed round of $30.7M, announced in Aug 2025.
Who founded aTyr Pharma?
FundedIQ lists Xiang Lei Yang (Founder) at aTyr Pharma.
Where is aTyr Pharma headquartered?
aTyr Pharma is based in San Diego, California, United States.
How many employees does aTyr Pharma have?
aTyr Pharma is in the 51-100 employee band.
How does aTyr Pharma's funding compare to other Biotechnology startups?
aTyr Pharma's latest round of $30.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's aTyr Pharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for aTyr Pharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.